Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Follow-Up Shows Favorable Results With Acalabrutinib in MCL

Key clinical point: Acalabrutinib monotherapy can produce durable responses in relapsed/refractory mantle cell lymphoma.

Major finding: The overall response rate was 81%, and the median duration of response was 26 months.

Study details: A phase 2 study of 124 patients with relapsed/refractory mantle cell lymphoma.

Disclosures: The study was sponsored by Acerta Pharma, a member of the AstraZeneca Group. The researchers reported relationships with AstraZeneca/Acerta Pharma and many other companies.


Wang M et al. Leukemia. 2019 Sep 26. doi: 10.1038/s41375-019-0575-9.